These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32236158)

  • 41. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?
    Ramamurthy C; Godwin JL; Borghaei H
    Curr Treat Options Oncol; 2017 Jun; 18(6):33. PubMed ID: 28534248
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Personalised cancer management: closer, but not here yet.
    Piccart M
    Ann Oncol; 2013 Aug; 24(8):1951-5. PubMed ID: 23878113
    [No Abstract]   [Full Text] [Related]  

  • 44. Present and future molecular testing of lung carcinoma.
    Dacic S; Nikiforova MN
    Adv Anat Pathol; 2014 Mar; 21(2):94-9. PubMed ID: 24508692
    [TBL] [Abstract][Full Text] [Related]  

  • 45. From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer.
    Formisano L; Jansen VM; Marciano R; Bianco R
    Anticancer Agents Med Chem; 2018; 18(9):1235-1240. PubMed ID: 28901258
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunotherapies for Lung Cancer.
    Gubens MA
    J Natl Compr Canc Netw; 2017 May; 15(5S):692-695. PubMed ID: 28515246
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
    Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
    J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A decade of advances in treatment for advanced non-small cell lung cancer.
    Gettinger S; Lynch T
    Clin Chest Med; 2011 Dec; 32(4):839-51. PubMed ID: 22054890
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recent progress in systemic treatment for lung cancer.
    Clark JW; Longo DL
    Curr Opin Pulm Med; 2018 Jul; 24(4):355-366. PubMed ID: 29697418
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor.
    Kunimasa K; Nakamura H; Sakai K; Kimura M; Inoue T; Tamiya M; Nishino K; Kumagai T; Nakatsuka S; Endo H; Inoue M; Nishio K; Imamura F
    Ann Oncol; 2018 Oct; 29(10):2145-2147. PubMed ID: 30099497
    [No Abstract]   [Full Text] [Related]  

  • 52. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
    Omori S; Kenmotsu H; Abe M; Watanabe R; Sugino T; Kobayashi H; Nakashima K; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Ohde Y; Endo M; Akiyama Y; Nakajima T; Takahashi T
    Int J Clin Oncol; 2018 Dec; 23(6):1052-1059. PubMed ID: 29948239
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The molecular markers related to personalized therapy of non-small cell lung cancer].
    Guo N; Yu C; Yu C
    Zhongguo Fei Ai Za Zhi; 2011 Mar; 14(3):292-6. PubMed ID: 21426677
    [No Abstract]   [Full Text] [Related]  

  • 54. Statistical and practical considerations for clinical evaluation of predictive biomarkers.
    Polley MY; Freidlin B; Korn EL; Conley BA; Abrams JS; McShane LM
    J Natl Cancer Inst; 2013 Nov; 105(22):1677-83. PubMed ID: 24136891
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunotherapy for lung cancer: Targeting the PD-1 pathway.
    Vafadar S
    JAAPA; 2017 Jun; 30(6):48-50. PubMed ID: 28538431
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.
    Villaruz LC; Socinski MA
    Clin Pharmacol Ther; 2016 Sep; 100(3):212-4. PubMed ID: 27090296
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer.
    Rivera N; Boada A; Bielsa MI; Fernández-Figueras MT; Carcereny E; Moran MT; Ferrándiz C
    JAMA Dermatol; 2017 Nov; 153(11):1162-1165. PubMed ID: 28700789
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.
    Monteiro ID; Califano R; Mountzios G; de Mello RA
    Future Oncol; 2016 Feb; 12(4):551-64. PubMed ID: 26776915
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeted Therapies in Non-small-Cell Lung Cancer.
    Hill A; Gupta R; Zhao D; Vankina R; Amanam I; Salgia R
    Cancer Treat Res; 2019; 178():3-43. PubMed ID: 31209840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.